Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249473 | 0.93 | ELANE (0.34) | ELANECYP19A1 | |
| SCHEMBL8261951 | 0.92 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL15325939 | 0.92 | ELANE (0.34) | ELANECYP19A1BIRC2XIAPBIRC3 | |
| SCHEMBL15213290 | 0.88 | ELANE (0.43) | ELANECYP19A1BIRC2 | |
| SCHEMBL16413340 | 0.88 | ELANE (0.43) | ELANECYP19A1BIRC2 | |
| SCHEMBL8205537 | 0.88 | ELANE (0.35) | ELANE | |
| SCHEMBL9966828 | 0.86 | ELANE (0.36) | ELANEBIRC2XIAPBIRC3 | |
| SCHEMBL9966596 | 0.86 | ELANE (0.36) | ELANEBIRC2XIAPBIRC3 | |
| SCHEMBL10314210 | 0.84 | ELANE (0.31) | ELANE | |
| SCHEMBL16418965 | 0.82 | ABHD6 (0.34) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910404-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1910404-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8216999-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-1924593-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-1924593-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO INC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470664-B2 | HCV NS3 protease inhibitors | MERCK & CO., INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1924593-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1910404-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015787-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015855-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027071-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027071-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | ELANE 435/4885CYP19A1 1462/4885BIRC2 1232/4885 |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | ELANE 435/4885CYP19A1 1462/4885BIRC2 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.